Close

Professor David Moore

MBChB MD DTM&H MSc (Epi) FRCP

Professor
of Infectious Diseases and Tropical Medicine

Room
Room 308

LSHTM
Keppel Street
London
WC1E 7HT
United Kingdom

Tel.
+44 (0)20 7927 2142

In my current position I have three roles - I lead a TB research group in Lima, Peru; I am Course Director for the DTM&H; and I am Consultant in Infectious Diseases and Tropical Medicine at the Hospital for Tropical Diseases in London.

Four years after graduating from Birmingham Medical School in 1989 I found myself working at Hlabisa Hospital in rural Kwazulu-Natal in South Africa. It was here that my eyes were opened to tropical medicine and public health. On returning to the UK I was fortunate to get onto the North Thames ID training rotation culminating in a year at the Hospital for Tropical Diseases.

After a 2001/2002 Masters in Epidemiology at the school we moved to Lima, Peru with a Wellcome Trust Research Training Fellowship in Clinical Tropical Medicine to evaluate the rapid TB and MDRTB diagnostic test MODS (www.modsperu.org) in the laboratory of JHU Professor Bob Gilman at Universidad Peruana Caytano Heredia (http://www.upch.edu.pe/).

With a few minor tweaks MODS has been transformed from an interesting research observation into a formally recognised rapid diagnostic test endorsed by WHO in 2010 and with further Wellcome support through a Career Development Fellowship we were able to evaluate the process of implementation of MODS into the Peruvian National TB Control Programme (NTP) and Regional Reference Laboratory Network. At $5.00 for an TB detection and MDR test available within 7 days MODS represents good value for money in this MDR high-burden setting.

The success of this work generated several additional questions, amongst them -

can MODS be used to diagnose XDRTB? (it can)

can MODS be developed into an off-the-shelf kit that performs just as well? (it can)

what should be/can be done for household contacts of MDRTB patients? (as yet unanswered)

what should be/can be done for patients with isoniazid-resistant non-MDR disease? (as yet unanswered)

The success of our research effort in Peru is largely a result of excellent collaborative links with the Peruvian NTP and with ID and chest physicians in the major Lima hospitals. Thus our work is integrated from the outset and only follows an agenda that is acceptable and prioritised in-country, maximising the likelihood of policy adoption at the end of the process.

Affiliations

Faculty of Infectious and Tropical Diseases
Department of Clinical Research

Centres

Tuberculosis (TB) Centre

Teaching

My main teaching responsibility at LSHTM is as Course Director for the DTM&H (http://www.lshtm.ac.uk/prospectus/short/stmh.html); I am also a tutor for the MSc in Tropical Medicine and International Health and the MSc in Control of Infectious Diseases.

During my 7 years in Lima I was privileged to supervise and mentor a large number of extremely talented and dynamic science and medical undergraduates and postgraduates from the UK, Peru and the US who passed through our research unit. Their names are too numerous to mention but most of them feature on at least one and often two of the publications on our publication list.

My research group in Lima remains active and postgraduate students from LSHTM and elsewhere are welcomed, though a good command of Spanish is a prerequisite.

Research

My primary research interest is in control of tuberculosis and drug-resistant tuberculosis through innovative strategies for diagnosis of adult and paediatric TB, management of latent TB infection and active TB disease (drug-susceptible and drug-resistant), and institutional and domestic TB infection control.

MODS delivers rapid, low-cost diagnosis of MDR-TB but important by-products of this enhanced diagnostic testing include identification of a large number of MDR-exposed household contacts and individuals with isoniazid resistant (non-MDR) TB. My group is exploring transcriptomic responses to preventive therapy for contacts exposed to drug-susceptible TB with an eye to future evaluations of preventive therapy for MDR-exposed contacts. We are also working on development of a MDR contact registry to enhance capacity of programmes to identify and track MDR contacts and to create a ready-to-go line list of individuals eligible for MDR preventive therapy in the event that current ongonig trials identify an efficacious regimen.

We also have a growing interest in development of laboratory capacity through innovative laboratory design and application of portable containerized laboratories.

An expanding area of interest is control of bartonellosis (Oroya fever, Verruga Peruana) due to Bartonella bacilliformis; knowledge gaps in diagnosis, natural history, epidemiology, vector biology and therapeutics are amongst the major challenges for this neglected disease affecting impoverished Andean communities. We have started to grow a research collaboration with Peruvian academic and Ministry of Health partners in order to undertake a major programme of research with a view to development of an agenda for disease control and ultimately elimination.

In London, aligned with my clinical tropical medicine practice at the Hospital for Tropical Diseases (UCLH), we are leading operational research into implementation of screening for Chagas disease in Latin American migrants now living in the UK. We have established a UK Chagas Hub for clinicians, scientists and members of the Latin American community to come together to explore ways to optimise clinical pathways, raise awareness and undertake research. http://www.thehtd.org/chagasuk.aspx

Research Area
Diagnostics
Health services research
Pharmacokinetics
Discipline
Epidemiology
Microbiology
Operational research
Disease and Health Conditions
Infectious disease
Tuberculosis
Chagas Disease
Tropical diseases
Country
United Kingdom
Pakistan
Peru
Somalia
Uganda
South Africa
Region
Latin America & Caribbean (developing only)
Sub-Saharan Africa (developing only)

Selected Publications

Linezolid for drug-susceptible tuberculosis.
Ahmed S; Moore DA; Nimmo C; Nunn AJ; Yates TA; North London TB Journal Club
2019
LANCET INFECTIOUS DISEASES
Implementation science to improve the quality of tuberculosis diagnostic services in Uganda.
Cattamanchi A; Berger CA; Shete PB; Turyahabwe S; Joloba M; Moore DA; Davis LJ; Katamba A
2019
Journal of clinical tuberculosis and other mycobacterial diseases
Quality of care for patients evaluated for tuberculosis in the context of Xpert MTB/RIF scale-up
Farr K; Nalugwa T; Ojok C; Nantale M; Nabwire S; Oyuku D; Shete PB; Han AH; Fielding K; Joloba M
2019
Journal of Clinical Tuberculosis and Other Mycobacterial Diseases
Vulnerable populations and the right to health: lessons from the Peruvian Amazon around tuberculosis control.
Gianella C; Pesantes MA; Ugarte-Gil C; Moore DAJ; Lema C
2019
INTERNATIONAL JOURNAL FOR EQUITY IN HEALTH
Rhombencephalitis and Myeloradiculitis Caused by a European Subtype of Tick-Borne Encephalitis Virus.
Neill L; Checkley AM; Benjamin LA; Herdman MT; Carter DP; Pullan ST; Aarons E; Griffiths K; Monaghan B; Karunaratne K
2019
Emerging infectious diseases
World Tuberculosis Day March 24th 2019 Theme: "It's TIME" - International Journal of Infectious Diseases Tuberculosis Theme Series.
Petersen E; Rao M; Ippolito G; Gualano G; Chakaya J; Ntoumi F; Moore D; Allen R; Gaskell K; Öhd JN
2019
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
Diabetes is associated with genotypically drug-resistant tuberculosis.
Ruesen C; Chaidir L; Ugarte-Gil C; van Ingen J; Critchley JA; Hill PC; Ruslami R; Santoso P; Huynen MA; Dockrell HM
2019
The European respiratory journal
Diabetes Mellitus Among Pulmonary Tuberculosis Patients From 4 Tuberculosis-endemic Countries: The TANDEM Study.
Ugarte-Gil C; Alisjahbana B; Ronacher K; Riza AL; Koesoemadinata RC; Malherbe ST; Cioboata R; Llontop JC; Kleynhans L; Lopez S
2019
Clinical infectious diseases
See more Publications